Antibodies, Monoclonal, Humanized

Name
Antibodies, Monoclonal, Humanized
Accession Number
DBCAT000014
Description

Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.

Drugs
DrugDrug Description
CetuximabAn endothelial growth factor receptor binding fragment used to treat colorectal cancer as well as squamous cell carcinoma of the head and neck.
OmalizumabA monoclonal anti-immunoglobulin E antibody used in the treatment of severe asthma and chronic idiopathic urticaria.
AdalimumabA monoclonal anti-tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis.
TrastuzumabA monoclonal anti-human epidermal growth factor receptor 2 protein antibody used to treat HER2-positive breast, gastroesophageal, and gastric cancers.
NatalizumabA monoclonal anti-integrin antibody which binds to the alpha 4 subunit of integrins to prevent migration of immune cells, and is used to treat Crohn's disease or multiple sclerosis.
PalivizumabA monoclonal anti respiratory syncytial virus F protein antibody used to prevent serious sequelae caused by respiratory syncytial virus infection in pediatric patients.
BevacizumabA monoclonal anti-vascular endothelial growth factor antibody used in combination with antineoplastic agents for the treatment of many types of cancer.
RanibizumabA recombinant humanized monoclonal antibody and VEGF-A antagonist used for the management of macular edema after retinal vein occlusion, age-related macular degeneration (wet), and diabetic macular edema.
UstekinumabA targeted antibody therapy used to manage inflammatory conditions such as plaque psoriasis, psoriatic arthritis, Crohn's Disease, and ulcerative colitis.
DenosumabA RANK ligand (RANKL) inhibitor used for the management of osteoporosis in patients at high risk for bone fractures.
NivolumabA PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma.
IpilimumabA human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma.
IdarucizumabAn antibody that binds dabigatran for the reversal of anticoagulant effects of dabigatran.
AtezolizumabA monoclonal antibody used to treat advanced or metastatic urothelial carcinoma with disease progression during or up to 12 months after platinum-containing chemotherapy.
OcrelizumabA CD20 specific monoclonal antibody used to treat relapsing remitting multiple sclerosis.
LanadelumabA plasma kallikrein inhibitor used to treat attacks of hereditary angioedema.
GalcanezumabA calcitonin-gene related peptide antagonist used to prevent migraines and treat cluster headaches.
RavulizumabA monoclonal antibody used to treat paroxysmal nocturnal hemoglobinuria.
RisankizumabAn interleukin-23 antagonist used to treat moderate to severe plaque psoriasis.
AbciximabA monoclonal anti-glycoprotein IIb/IIIa receptor antibody used to prevent thrombosis during percutaneous coronary intervention.
BasiliximabA monoclonal anti-C25 antibody (interleukin-2 receptor alpha subunit) used as immunosuppressive therapy in kidney transplant patients.
AlemtuzumabA monoclonal anti-CD52 antibody used in the treatment of B-cell chronic lymphocytic leukemia and relapsing forms of multiple sclerosis.
DaclizumabA monoclonal anti-CD25 antibody that blocks the interleukin-2 receptor which is used to treat relapsing forms of multiple sclerosis.
PanitumumabA recombinant humanized monoclonal antibody used to treat EGFR-expressing, metastatic colorectal carcinoma that is refractory to fluoropyrimidine-, oxaliplatin-, and irinotecan- containing chemotherapy regimens.
Trastuzumab emtansineAn antineoplastic agent and antibody-drug conjugate used to treat HER2-overexpressing breast cancer.
Bevacizumab zirconium Zr-89Bevacizumab zirconium Zr-89 is under investigation in clinical trial NCT01338090 (89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors).
CrizanlizumabA monoclonal antibody that targets selectin to reduce the frequency of vasooclusive crises in patients with sickle cell disease.
Enfortumab vedotinAn antibody-drug conjugate comprised of a fully human monoclonal antibody and microtubule-disrupting chemotherapeutic agent used in the treatment of advanced or metastatic urothelial cancer.
FremanezumabA humanized monoclonal antibody directed against human calcitonin-gene related peptide to prevent migraines.
SatralizumabA subcutaneously injected anti-IL-6 receptor monoclonal antibody for the treatment of neuromyelitis optica spectrum disorder (NMOSD).
OdesivimabPart of a product containing three monoclonal IgG1κ antibodies directed against the GP1,2 glycoprotein of Zaire ebolavirus. Together, these three antibodies act to neutralize viral particles and to recruit immune effectors for the destruction of both viral particles and infected cells.
MaftivimabPart of a product containing three monoclonal IgG1κ antibodies directed against the GP1,2 glycoprotein of Zaire ebolavirus. Together, these three antibodies act to neutralize viral particles and to recruit immune effectors for the destruction of both viral particles and infected cells.
AtoltivimabPart of a product containing three monoclonal IgG1κ antibodies directed against the GP1,2 glycoprotein of Zaire ebolavirus. Together, these three antibodies act to neutralize viral particles and to recruit immune effectors for the destruction of both viral particles and infected cells.
BamlanivimabA neutralizing human IgG1κ monoclonal antibody against the SARS-CoV-2 spike (S) protein for use in patients aged 12 and over at high risk of developing severe COVID-19.
NaxitamabA GD2-targeted IgG1 monoclonal antibody for the treatment of high-risk relapsed/refractory neuroblastoma of the bone or bone marrow.
Polatuzumab vedotinA CD79b antibody conjugate indicated to treat relapsed or refractory B-cell lymphoma.
AbituzumabAbituzumab has been used in trials studying the treatment of Prostate Cancer Metastatic.
Belantamab mafodotinAn anti B-cell maturation antigen antibody conjugated to a microtubule inhibitor to treat relapsed or refractory multiple myeloma.
Cantuzumab ravtansineInvestigated for use/treatment in gastric cancer.
Cergutuzumab amunaleukinCergutuzumab amunaleukin is under investigation in clinical trial NCT02004106 (A Study to Evaluate Safety, Pharmacokinetics, and Efficacy of RO6895882 in Participants With Advanced and/or Metastatic Solid Tumors).
Certolizumab pegolA tumor necrosis factor (TNF) blocker used to treat a variety of autoimmune and autoinflammatory conditions like Crohn's disease, rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, and plaque psoriasis.
DalotuzumabDalotuzumab has been investigated for the treatment of Breast Cancer, Non Small Cell Lung Cancer, and Metastatic Colorectal Cancer.
Dapirolizumab pegolDapirolizumab pegol is under investigation in clinical trial NCT02804763 (A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus).
DemcizumabDemcizumab is under investigation for the treatment of Nonsquamous Nonsmall Cell Neoplasm of Lung.
Depatuxizumab mafodotinNo approved indication.
ElotuzumabAn antineoplastic agent and SLAMF7-directed immunostimulatory antibody used for the treatment of refractory multiple myeloma in combination with other antineoplastic agents.
EmibetuzumabEmibetuzumab has been used in trials studying the treatment of Advanced Cancer, Renal Cell Carcinoma, Hepatocellular Cancer, Gastric Adenocarcinoma, and Non-Small Cell Lung Cancer, among others.
EnokizumabInvestigated for use/treatment in asthma.
EpratuzumabInvestigated for use/treatment in leukemia (lymphoid), lymphoma (non-hodgkin's), and systemic lupus erythematosus.
EtaracizumabEtaracizumab has been investigated for the treatment of Psoriasis, Renal Cell Carcinoma, Stage IV Renal Cell Cancer, Recurrent Renal Cell Cancer, and Stage III Renal Cell Cancer.
FarletuzumabInvestigated for use/treatment in ovarian cancer.
FiclatuzumabFiclatuzumab has been used in trials studying the treatment of Acute Myeloid Leukemia, Non-small Cell Lung Cancer, Mullerian Mixed Tumor of Ovary, Relapsed Acute Myeloid Leukemia, and Refractory Acute Myeloid...
Gemtuzumab ozogamicinA monoclonal anti-CD33 antibody used to treat CD33-positive acute myeloid leukemia.
GevokizumabGevokizumab has been used in trials studying the treatment of Acne Vulgaris, Osteoarthritis, Behcet's Uveitis, Pyoderma Gangrenosum, and Behcet's Disease Uveitis, among others. Gevokizumab acts as a modulator of cytokine...
GosuranemabGosuranemab is under investigation in clinical trial NCT02460094 (Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy).
Inotuzumab ozogamicinAn antibody-drug conjugate used to treat B-cell precursor acute lymphoblastic leukemia (ALL).
IxekizumabA monoclonal antibody used to treat moderate to severe plaque psoriasis.
Ladiratuzumab vedotinLadiratuzumab vedotin is under investigation in clinical trial NCT01969643 (A Safety Study of SGN-LIV1A in Breast Cancer Patients).
LebrikizumabLebrikizumab has been used in trials studying the treatment of Asthma, Allergic Asthma, Atopic Dermatitis, Idiopathic Pulmonary Fibrosis, and COPD, Chronic Obstructive Pulmonary Disease.
Lifastuzumab vedotinLifastuzumab vedotin is under investigation in clinical trial NCT01363947 (Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer).
LintuzumabLintuzumab is under investigation in clinical trial NCT00016159 (Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia).
Lorvotuzumab mertansineLorvotuzumab mertansine has been used in trials studying the treatment of SCLC, Leukemia, Ovarian Cancer, Multiple Myeloma, and Merkel Cell Carcinoma, among others.
Lulizumab pegolLulizumab pegol is under investigation in clinical trial NCT02843659 (Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome).
MargetuximabAn Fc-engineered human/mouse chimeric IgG1κ anti-HER2 monoclonal antibody indicated for patients with HER2-positive metastatic breast cancer.
ObinutuzumabAn antineoplastic CD20 antibody used to treat untreated chronic lymphocytic leukemia in combination with chlorambucil.
OnartuzumabOnartuzumab has been used in trials studying the treatment of Neoplasms, Lung Cancer, Glioblastoma, Gastric Cancer, and Colorectal Cancer, among others.
Oportuzumab monatoxInvestigated for use/treatment in bladder cancer and head and neck cancer.
OtlertuzumabOtlertuzumab is under investigation in clinical trial NCT01188681 (Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia).
OzanezumabOzanezumab has been used in trials studying the treatment of Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Multiple Sclerosis, Relapsing-Remitting.
PertuzumabAn antineoplastic agent used in the treatment of HER2-positive metastatic breast cancer in combination with other antineoplastic agents.
Pinatuzumab vedotinPinatuzumab vedotin is under investigation in clinical trial NCT01691898 (A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With...
PonezumabPonezumab is under investigation in clinical trial NCT00607308 (A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease).
RefanezumabRefanezumab is under investigation in clinical trial NCT00833989 (Safety Escalating Repeat IV, in Stroke Patients).
RomosozumabA monoclonal antibody used to treat osteoporosis in postmenopausal women at high risk of fracture, patients who are intolerant of other treatments, or patients who have failed other treatments.
Rovalpituzumab tesirineRovalpituzumab Tesirine has been used in trials studying the treatment of GLIOBLASTOMA, Malignant Melanoma, Other Solid Tumors, Small Cell Lung Cancer, and Medullary Thyroid Cancer, among others.
Sacituzumab govitecanSacituzumab govitecan targets TROP-2-expressing cancer cells through a humanized antibody (RS7) before subsequently becoming internalized and releasing the topoisomerase I inhibitor SN-38 to induce DNA damage-mediated apoptosis.[L13002]
SibrotuzumabInvestigated for use/treatment in cancer/tumors (unspecified), colorectal cancer, and lung cancer.
Sofituzumab vedotinSofituzumab vedotin is under investigation in clinical trial NCT01335958 (Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer).
Telisotuzumab vedotinTelisotuzumab vedotin is under investigation in clinical trial NCT02099058 (A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Subjects With Advanced Solid Tumors.).
TildrakizumabAn interleukin-23 antagonist used to treat moderate to severe plaque psoriasis.
Trastuzumab duocarmazineTrastuzumab duocarmazine is under investigation in clinical trial NCT03262935 (SYD985 vs. Physician's Choice in Participants With Her2-positive Locally Advanced or Metastatic Breast Cancer).
Tucotuzumab celmoleukinTucotuzumab celmoleukin is under investigation in clinical trial NCT00016237 (Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous...
Vorsetuzumab mafodotinVorsetuzumab mafodotin is under investigation in clinical trial NCT01677390 (A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma).
AnrukinzumabAnrukinzumab has been used in trials studying the diagnostic of Asthma.
ApolizumabInvestigated for use/treatment in lymphoma (non-hodgkin's), leukemia (lymphoid), and solid tumors.
BapineuzumabBapineuzumab has been investigated for the treatment of Alzheimer's Disease.
BemarituzumabBemarituzumab is under investigation in clinical trial NCT03694522 (A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (Mfolfox6) in Gastric/gastroesophageal Junction Cancer (FIGHT)).
BenralizumabA monoclonal antibody used to treat eosinophilic asthma.
BimekizumabBimekizumab has been used in trials studying the treatment of Psoriatic arthritis, Ankylosing Spondylitis, Chronic Plaque Psoriasis, and Mild to Moderate Psoriasis.
BivatuzumabInvestigated for use/treatment in cancer/tumors (unspecified) and head and neck cancer.
BlosozumabBlosozumab has been used in trials studying the basic science and treatment of Osteoporosis and Osteoporosis, Postmenopausal.
BococizumabBococizumab has been used in trials studying the treatment and prevention of Dyslipidemia, Hyperlipidemia, Hypercholesterolemia, Cardiovascular Disease, and Heterozygous Familial Hypercholesterolemia.
BrolucizumabAn anti VEGF-A monoclonal antibody indicated to treat neovascular age related macular degeneration.
BrontictuzumabBrontictuzumab has been used in trials studying the treatment of Adenoid Cystic Carcinoma, Relapsed or Refractory Solid Tumors, and Relapsed or Refractory Lymphoid Malignancies.
CabiralizumabCabiralizumab is under investigation in clinical trial NCT03502330 (APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma).
CamrelizumabCamrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).
CaplacizumabA von Willebrand factor (vWF)-directed antibody fragment used to treat acquired thrombotic thrombocytopenic purpura (aTTP).
ClazakizumabClazakizumab has been used in trials studying the treatment of Rheumatoid Arthritis.
CodrituzumabCodrituzumab is under investigation in clinical trial NCT01507168 (A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma).
ConcizumabConcizumab has been used in trials studying the treatment of Haemophilia A and Congenital Bleeding Disorder.
CrenezumabCrenezumab has been used in trials studying the treatment of Alzheimer's Disease.
CusatuzumabCusatuzumab is under investigation in clinical trial NCT01813539 (Phase 1/2 Study of ARGX-110 in Patients With Advanced Malignancies).
DacetuzumabInvestigated for use/treatment in lymphoma (non-hodgkin's) and multiple myeloma.
DezamizumabDezamizumab is under investigation in clinical trial NCT03417830 (Biodistribution of 89Zirconium-labelled GSK2398852 Using PET Imaging).
DomagrozumabDomagrozumab is under investigation in clinical trial NCT01616277 (A Phase 1 Study To Evaluate The Safety And Tolerability Of PF-06252616 In Healthy Subjects).
DostarlimabAn anti-PD-1 monoclonal antibody used in the treatment of mismatch repair deficient endometrial cancers.
DuligotuzumabDuligotuzumab has been used in trials studying the treatment of Neoplasms, Colorectal Cancer, Head and Neck Cancer, and Epithelial Tumors, Malignant.
EculizumabA recombinant humanized monoclonal antibody used to reduce the risk of hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
EfalizumabA monoclonal anti-CD11a antibody used to treat moderate to severe plaque psoriasis.
EmactuzumabEmactuzumab is under investigation in clinical trial NCT01494688 (A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors).
EmicizumabAn antibody against Factor IXa and Factor X used to treat hemophilia A.
EnoblituzumabEnoblituzumab is under investigation in clinical trial NCT02982941 (Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors).
EptinezumabA monoclonal antibody directed against CGRP infused every 3 months for the preventive treatment of migraine in adults.
EtrolizumabEtrolizumab has been used in trials studying the treatment of Crohn Disease and Ulcerative Colitis.
FaricimabAn IgG1-derived bispecific antibody against VEGF-A and Ang-2 for the treatment of retinal vascular diseases such as diabetic macular edema, age-related macular degeneration, and retinal vein occlusion.
FlotetuzumabFlotetuzumab is under investigation in clinical trial NCT02152956 (Safety Study of MGD006 in Relapsed/Refractory Acute Myeloid Leukemia (AML) or Intermediate-2/High Risk MDS).
FontolizumabInvestigated for use/treatment in crohn's disease and psoriasis and psoriatic disorders.
FrovocimabFrovocimab is under investigation in clinical trial NCT01671085 (A Study of LY3015014 in Healthy Participants With High Cholesterol).
IbalizumabA CD4-specific antibody used to treat HIV infections.
ImgatuzumabImgatuzumab is under investigation in clinical trial NCT01326000 (A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With...
InebilizumabA humanized anti-CD19 cytolytic monoclonal antibody for B-cell depletion in autoimmune conditions. Currently approved only for neuromyelitis optica spectrum disorder (NMOSD).
ItolizumabItolizumab is under investigation in clinical trial NCT04605926 (A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19).
LabetuzumabLabetuzumab is a humanized monoclonal antibody used to treat cancer. Retrieved from "http://en.wikipedia.org/wiki/Labetuzumab"
LacnotuzumabLacnotuzumab is under investigation in clinical trial NCT01643850 (MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)).
LampalizumabLampalizumab has been used in trials studying the treatment of Geographic Atrophy.
LandogrozumabLandogrozumab has been used in trials studying the treatment of Advanced Cancer, Muscular Atrophy, and Pancreatic Cancer.
LeronlimabA humanized monoclonal antibody being investigated
LigelizumabLigelizumab has been used in trials studying the basic science and treatment of Asthma, Allergy, Peanut Allergy, Allergic Asthma, and Atopic Dermatitis, among others.
LumretuzumabLumretuzumab has been used in trials studying the treatment of Neoplasms, Breast Cancer, Squamous Non-Small Cell Lung Cancer, and Non-Squamous Non-Small Cell Lung Cancer.
LutikizumabLutikizumab is under investigation in clinical trial NCT02087904 (A Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients With Knee Osteoarthritis).
MatuzumabInvestigated for use/treatment in cervical dysplasia/cancer, colorectal cancer, gastric cancer, and lung cancer.
MepolizumabA fully-humanized monoclonal IgG1 kappa anti-IL-5 antibody used in conjunction with other therapies to treat severe asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome.
MilatuzumabMilatuzumab has been used in trials studying the treatment of Lupus Nephritis, Multiple Myeloma (MM), GVHD (Acute or Chronic), Myelodysplastic Syndrome, and Chronic Lymphocytic Leukemia, among others.
MirikizumabMirikizumab is under investigation in clinical trial NCT03053622 (A Study of Mirikizumab (LY3074828) Injection in Healthy Participants).
MogamulizumabA monoclonal antibody used to treat relapsed or refractory mycosis fungoides or Sézary syndrome after attempting one other therapy.
MonalizumabMonalizumab has been used in trials studying the treatment of Gynecologic Cancer, Chronic Lymphocytic Leukemia, and Squamous Cell Carcinoma of the Oral Cavity.
MosunetuzumabMosunetuzumab is under investigation in clinical trial NCT03677154 (A Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Therapy in...
MotavizumabInvestigated for use/treatment in viral infection and pediatric indications.
NemolizumabNemolizumab is under investigation in clinical trial NCT03921411 (A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Subjects With Atopic Dermatitis (AD)).
NimotuzumabAn EGFR-targeting monoclonal antibody used in the treatment of squamous cell carcinomas of the head and neck and glioblastomas.
OlendalizumabOlendalizumab is under investigation in clinical trial NCT01883544 (Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALXN1007 in Healthy Male and Female Subjects).
OlokizumabOlokizumab has been used in trials studying the treatment of Crohn's Disease.
OzoralizumabOzoralizumab has been used in trials studying the treatment of Rheumatoid Arthritis and Active Rheumatoid Arthritis.
ParsatuzumabParsatuzumab is under investigation in clinical trial NCT01366131 (Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous...
PascolizumabInvestigated for use/treatment in asthma.
PateclizumabPateclizumab is under investigation in clinical trial NCT01225393 (A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in...
PembrolizumabA PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma.
PexelizumabFor the treatment of inflammation during cardiac surgery.
PidilizumabPidilizumab is under investigation in clinical trial NCT01952769 (Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma).
PlozalizumabPlozalizumab has been investigated for the treatment of Atherosclerosis. Plozalizumab, a novel humanized monoclonal antibody, specifically targets CCR2 chemokine receptors found on the surface of certain white blood cells including...
VonlerolizumabVonlerolizumab is under investigation in clinical trial NCT03029832 (A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who...
PrasinezumabPrasinezumab is under investigation in clinical trial NCT03100149 (A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease).
QuilizumabQuilizumab is under investigation in clinical trial NCT01160861 (A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MEMP1972A in Patients With Allergic Rhinitis).
RavagalimabRavagalimab is under investigation in clinical trial NCT03695185 (A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe It Is in Participants With Moderate to Severe Ulcerative Colitis...
ReslizumabAn IL-5 antagonist used as an add-on maintenance treatment of patients with severe eosinophilic asthma in adults.
RontalizumabRontalizumab has been used in trials studying the treatment of Systemic Lupus Erythematosus.
RuplizumabInvestigated for use/treatment in thrombocytopenia, systemic lupus erythematosus, transplant (rejection), blood (blood forming organ disorders, unspecified), and multiple sclerosis.
SamalizumabSamalizumab has been used in trials studying the treatment of Multiple Myeloma and B-cell Chronic Lymphocytic Leukemia.
SimtuzumabSimtuzumab has been used in trials studying the treatment and basic science of Myelofibrosis, Pancreatic Cancer, Colorectal Cancer, and Idiopathic Pulmonary Fibrosis.
SiplizumabInvestigated for use/treatment in psoriasis and psoriatic disorders, transplant (rejection), graft versus host disease, lymphoma (unspecified), and leukemia (unspecified).
SolanezumabSolanezumab is under investigation for the treatment of Dementia, Alzheimers Disease, and Alzheimers Disease, Familial.
SonepcizumabInvestigated for use/treatment in solid tumors.
SpartalizumabSpartalizumab is under investigation in clinical trial NCT02605967 (Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma).
TalacotuzumabTalacotuzumab is under investigation in clinical trial NCT01632852 (A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission).
TanezumabTanezumab has been investigated for the treatment of Osteoarthritis, Knee and Neuralgia, Postherpetic.
TefibazumabTefibazumab is under investigation in clinical trial NCT00198289 (Aurexis® in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs).
TelisotuzumabTelisotuzumab is under investigation in clinical trial NCT01472016 (Study of ABT-700 in Subjects With Advanced Solid Tumors).
TeplizumabInvestigated for use/treatment in diabetes mellitus type 1.
TibulizumabTibulizumab is under investigation in clinical trial NCT03736772 (A Study of LY3090106 in Japanese and Caucasian Healthy Participants).
TigatuzumabTigatuzumab is under investigation in clinical trial NCT00991796 (CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC)).
TislelizumabTislelizumab is under investigation in clinical trial NCT02660034 (The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors).
TocilizumabAn interleukin-6 (IL-6) receptor antagonist used to treat Cytokine Release Syndrome (CRS), Systemic Juvenile Idiopathic Arthritis (sJIA), Giant Cell Arteritis (GCA), and Rheumatoid Arthritis (RA).
TomuzotuximabTomuzotuximab is under investigation in clinical trial NCT02052960 (CetuGEX™ in Comparison to Cetuximab for the Treatment of Patients With Head and Neck Cancer).
ToralizumabToralizumab is under investigation in clinical trial NCT03605927 (CD40-L Blockade for Prevention of Acute Graft-versus-host Disease).
TregalizumabTregalizumab has been used in trials studying the treatment of Rheumatoid Arthritis.
VanucizumabVanucizumab has been used in trials studying the treatment of ColoRectal Cancer and Advanced/Metastatic Solid Tumors.
VatelizumabVatelizumab has been used in trials studying the treatment of Ulcerative Colitis.
VedolizumabAn integrin blocker and anti-inflammatory agent used to manage ulcerative colitis and Crohn's disease in adults with inadequate clinical response to immunomodulators.
VeltuzumabInvestigated for use/treatment in lymphoma (non-hodgkin's).
VisilizumabVisilizumab has been investigated for the treatment of Ulcerative Colitis.
VobarilizumabVobarilizumab is under investigation in clinical trial NCT02101073 (ALX-0061 Phase I Bioavailability Study in Healthy Volunteers).
VopratelimabVopratelimab is under investigation in clinical trial NCT02904226 (JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors).
VunakizumabVunakizumab is under investigation in clinical trial NCT03463187 (Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis).
XentuzumabXentuzumab is under investigation in clinical trial NCT02191891 (Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)).
ZenocutuzumabZenocutuzumab is under investigation in clinical trial NCT03321981 (MCLA-128 With Trastuzumab/chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer).
TafasitamabA CD19-directed cytolytic monoclonal antibody used in the treatment of B-cell malignancies.
Drugs & Drug Targets
DrugTargetType
CetuximabEpidermal growth factor receptortarget
CetuximabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
CetuximabComplement C1q subcomponent subunit Atarget
CetuximabComplement C1q subcomponent subunit Btarget
CetuximabComplement C1q subcomponent subunit Ctarget
CetuximabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
CetuximabHigh affinity immunoglobulin gamma Fc receptor Itarget
CetuximabLow affinity immunoglobulin gamma Fc region receptor II-atarget
OmalizumabHigh affinity immunoglobulin epsilon receptor subunit alphatarget
OmalizumabHigh affinity immunoglobulin epsilon receptor subunit betatarget
AdalimumabTumor necrosis factortarget
TrastuzumabReceptor tyrosine-protein kinase erbB-2target
NatalizumabIntegrin alpha-4target
NatalizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
NatalizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
NatalizumabIntercellular adhesion molecule 1target
PalivizumabFusion glycoprotein F0target
PalivizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
PalivizumabComplement C1r subcomponenttarget
PalivizumabComplement C1q subcomponent subunit Atarget
PalivizumabComplement C1q subcomponent subunit Btarget
PalivizumabComplement C1q subcomponent subunit Ctarget
PalivizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
PalivizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
PalivizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
BevacizumabVascular endothelial growth factor Atarget
BevacizumabComplement C1q subcomponent subunit Atarget
BevacizumabComplement C1q subcomponent subunit Btarget
BevacizumabComplement C1q subcomponent subunit Ctarget
BevacizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
BevacizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
RanibizumabVascular endothelial growth factor Atarget
UstekinumabInterleukin-12 subunit betatarget
UstekinumabInterleukin-23target
DenosumabTumor necrosis factor ligand superfamily member 11target
NivolumabProgrammed cell death protein 1target
IpilimumabCytotoxic T-lymphocyte protein 4target
AtezolizumabProgrammed cell death 1 ligand 1target
OcrelizumabB-lymphocyte antigen CD20target
LanadelumabPlasma kallikreintarget
GalcanezumabCalcitonin gene-related peptide 1target
GalcanezumabCalcitonin gene-related peptide 2target
RavulizumabComplement C5target
RisankizumabInterleukin-23target
AbciximabIntegrin beta-3target
AbciximabLow affinity immunoglobulin gamma Fc region receptor II-atarget
AbciximabLow affinity immunoglobulin gamma Fc region receptor II-btarget
AbciximabIntegrin alpha-IIbtarget
AbciximabVitronectintarget
BasiliximabInterleukin-2 receptor subunit alphatarget
BasiliximabInterleukin-2 receptor subunit betatarget
AlemtuzumabCAMPATH-1 antigentarget
AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
AlemtuzumabHigh affinity immunoglobulin gamma Fc receptor Itarget
AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DaclizumabInterleukin-2 receptor subunit alphatarget
DaclizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DaclizumabComplement C1r subcomponenttarget
DaclizumabComplement C1q subcomponent subunit Atarget
DaclizumabComplement C1q subcomponent subunit Btarget
DaclizumabComplement C1q subcomponent subunit Ctarget
DaclizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DaclizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DaclizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DaclizumabInterleukin-2 receptor subunit betatarget
DaclizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DaclizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
PanitumumabEpidermal growth factor receptortarget
Trastuzumab emtansineReceptor tyrosine-protein kinase erbB-2target
Trastuzumab emtansineP-glycoprotein 1transporter
Trastuzumab emtansineCytochrome P450 3A4enzyme
Trastuzumab emtansineCytochrome P450 3A5enzyme
CrizanlizumabP-selectintarget
Enfortumab vedotinCytochrome P450 3A4enzyme
Enfortumab vedotinNectin-4target
Enfortumab vedotinP-glycoprotein 1transporter
FremanezumabCalcitonin gene-related peptide 1target
FremanezumabCalcitonin gene-related peptide 2target
SatralizumabInterleukin-6 receptor subunit alphatarget
OdesivimabEnvelope glycoproteintarget
MaftivimabEnvelope glycoproteintarget
AtoltivimabEnvelope glycoproteintarget
BamlanivimabSpike glycoproteintarget
NaxitamabGD2 disialogangliosidetarget
Polatuzumab vedotinCytochrome P450 3A4enzyme
Polatuzumab vedotinB-cell antigen receptor complex-associated protein beta chaintransporter
Polatuzumab vedotinB-cell antigen receptor complex-associated protein beta chaintarget
Belantamab mafodotinSolute carrier organic anion transporter family member 1B1transporter
Belantamab mafodotinSolute carrier organic anion transporter family member 1B3transporter
Belantamab mafodotinMultidrug resistance-associated protein 1transporter
Belantamab mafodotinCanalicular multispecific organic anion transporter 1transporter
Belantamab mafodotinCanalicular multispecific organic anion transporter 2transporter
Belantamab mafodotinBile salt export pumptransporter
Belantamab mafodotinP-glycoprotein 1transporter
Belantamab mafodotinTumor necrosis factor receptor superfamily member 17target
Certolizumab pegolTumor necrosis factortarget
Certolizumab pegolAlcohol dehydrogenase [NADP(+)]enzyme
Depatuxizumab mafodotinEpidermal growth factor receptortarget
Depatuxizumab mafodotinTubulin beta chaintarget
ElotuzumabSLAM family member 7target
EpratuzumabB-cell receptor CD22target
FarletuzumabFolate receptor alphatarget
Gemtuzumab ozogamicinMyeloid cell surface antigen CD33target
Gemtuzumab ozogamicinLow affinity immunoglobulin gamma Fc region receptor III-Btarget
Gemtuzumab ozogamicinLow affinity immunoglobulin gamma Fc region receptor III-Atarget
Gemtuzumab ozogamicinHigh affinity immunoglobulin gamma Fc receptor Itarget
GevokizumabInterleukin-1 betatarget
Inotuzumab ozogamicinP-glycoprotein 1transporter
Inotuzumab ozogamicinB-cell receptor CD22target
IxekizumabInterleukin-17Atarget
LebrikizumabInterleukin-13target
LebrikizumabIL13 proteintarget
Lorvotuzumab mertansineCytochrome P450 3A4enzyme
MargetuximabReceptor tyrosine-protein kinase erbB-2target
ObinutuzumabB-lymphocyte antigen CD20target
Oportuzumab monatoxEpithelial cell adhesion moleculetarget
PertuzumabReceptor tyrosine-protein kinase erbB-2target
RomosozumabSclerostintarget
Sacituzumab govitecanTumor-associated calcium signal transducer 2target
Sacituzumab govitecanDNA topoisomerase 1target
Sacituzumab govitecanFar upstream element-binding protein 1target
Sacituzumab govitecanUDP-glucuronosyltransferase 1-1enzyme
SibrotuzumabSeprasetarget
TildrakizumabInterleukin-23target
TildrakizumabCytochrome P450 4A11enzyme
BenralizumabInterleukin-5 receptor subunit alphatarget
BenralizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
BivatuzumabCD44 antigentarget
BrolucizumabVascular endothelial growth factor Atarget
CamrelizumabProgrammed cell death protein 1target
Caplacizumabvon Willebrand factortarget
DacetuzumabTumor necrosis factor receptor superfamily member 5target
DostarlimabProgrammed cell death protein 1target
EculizumabComplement C5target
EfalizumabIntegrin alpha-Ltarget
EfalizumabIntegrin alpha-Xtarget
EmicizumabCoagulation factor IXtarget
EmicizumabCoagulation factor Xtarget
EptinezumabCalcitonin gene-related peptide 1target
EptinezumabCalcitonin gene-related peptide 2target
FaricimabVascular endothelial growth factor Atarget
FaricimabAngiopoietin-2target
FontolizumabInterferon gammatarget
IbalizumabT-cell surface glycoprotein CD4target
IbalizumabC-C chemokine receptor type 5target
IbalizumabC-X-C chemokine receptor type 4target
InebilizumabB-lymphocyte antigen CD19target
LabetuzumabCarcinoembryonic antigen-related cell adhesion molecule 5target
LeronlimabC-C chemokine receptor type 5target
MatuzumabEpidermal growth factor receptortarget
MepolizumabInterleukin-5target
MogamulizumabC-C chemokine receptor type 4target
PascolizumabInterleukin-4target
PembrolizumabProgrammed cell death protein 1target
PlozalizumabC-C chemokine receptor type 2target
ReslizumabInterleukin-5target
RuplizumabCD40 ligandtarget
SiplizumabT-cell surface antigen CD2target
SpartalizumabProgrammed cell death protein 1target
TislelizumabProgrammed cell death protein 1target
TocilizumabInterleukin-6 receptor subunit alphatarget
TocilizumabCytochrome P450 3A4enzyme
VedolizumabIntegrin alpha-4target
VedolizumabIntegrin beta-7target
TafasitamabB-lymphocyte antigen CD19target